HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Levetiracetam synergizes with gabapentin, pregabalin, duloxetine and selected antioxidants in a mouse diabetic painful neuropathy model.

AbstractRATIONALE:
We have reported that levetiracetam, a novel anticonvulsant with analgesic properties, synergizes with ibuprofen/aspirin/paracetamol in a model of diabetic painful neuropathy (DPN). Most guidelines recommend gabapentin, pregabalin, and duloxetine as first- or second-line agents for DPN.
OBJECTIVE:
We examined the effects of combination treatment of first-/second-line analgesics with levetiracetam in a model of DPN. Additionally, the levetiracetam's combinations with antioxidants, low dose of aspirin, coenzyme Q10, or α-lipoic acid were evaluated.
METHODS:
Diabetes was induced in C57BL/6 mice with a single high dose of streptozotocin. The antinociceptive effects of orally administered levetiracetam, gabapentin, pregabalin, duloxetine (acute treatment) and aspirin, coenzyme Q10, and α-lipoic acid (preventive 7-day treatment), as well as combinations of levetiracetam with individual drugs were examined in the tail-flick test. In combination experiments, the drugs were coadministered in fixed-dose fractions of single-drug ED50; the type of interaction was determined by isobolographic analysis.
RESULTS:
About 60-, 32-, 30-, 26-, 18-, and 6-fold reductions of doses of both drugs in levetiracetam combinations with pregabalin, gabapentin, coenzyme Q10, aspirin, duloxetine, and α-lipoic acid, respectively, were detected.
CONCLUSIONS:
Combinations of levetiracetam with gabapentin/pregabalin/duloxetine that target different mechanisms/sites of action involved in DPN, as well as combinations of levetiracetam and low-dose aspirin/coenzyme Q10/α-lipoic acid that target underlying causes of DPN, produce marked synergistic interactions in reducing nociception in diabetic mice. This suggests that these combination treatments might be of great benefit for diabetic patients and should be explored further in clinical trials.
AuthorsRadica Stepanović-Petrović, Ana Micov, Maja Tomić, Uroš Pecikoza
JournalPsychopharmacology (Psychopharmacology (Berl)) Vol. 234 Issue 11 Pg. 1781-1794 (Jun 2017) ISSN: 1432-2072 [Electronic] Germany
PMID28332005 (Publication Type: Journal Article)
Chemical References
  • Amines
  • Analgesics
  • Anticonvulsants
  • Antioxidants
  • Cyclohexanecarboxylic Acids
  • Levetiracetam
  • Pregabalin
  • gamma-Aminobutyric Acid
  • Gabapentin
  • Duloxetine Hydrochloride
  • Piracetam
Topics
  • Amines (administration & dosage)
  • Analgesics (administration & dosage)
  • Animals
  • Anticonvulsants (administration & dosage)
  • Antioxidants (administration & dosage)
  • Cyclohexanecarboxylic Acids (administration & dosage)
  • Diabetes Mellitus, Experimental (blood, drug therapy, pathology)
  • Diabetic Neuropathies (blood, drug therapy, pathology)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Duloxetine Hydrochloride (administration & dosage)
  • Gabapentin
  • Levetiracetam
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Piracetam (administration & dosage, analogs & derivatives)
  • Pregabalin (administration & dosage)
  • gamma-Aminobutyric Acid (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: